Compare stocks

Xvivo Perfusion AB is a biotechnology company specializing in the development and commercialization of medical devices and systems for organ transplantation. The company's core products include machine perfusion devices and solutions designed to preserve, evaluate, and transport donor organs, with a particular focus on lungs and hearts. Founded in 1998, Xvivo is headquartered in Gothenburg, Sweden, and has established a presence in key markets worldwide. The company's strategic positioning is enhanced by its commitment to improving transplantation outcomes through innovative technologies and research collaborations. Xvivo's expertise in organ preservation and perfusion technology provides competitive strengths in the field of regenerative medicine.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.